-
公开(公告)号：US20210290526A1
公开(公告)日：2021-09-23
申请号：US17257229
申请日：2019-07-01
发明人： Melanie DENKINGER , Ewald SCHLOTZER , Edmundo BRITO DE LA FUENTE , Lida A. Quinchia-Bustamante , Crispulo Gallegos-Montes
IPC分类号： A61K9/00 , A61K9/107 , A61K36/48 , A61K36/63 , A61K35/60 , A61K31/575 , A61K31/202 , A61K36/06 , A61K31/197 , A61K31/355 , A61K31/14 , A61P29/00 , A61P1/16
摘要： The present disclosure relates to lipid emulsions for parenteral administration, comprising 10 to 30% of a lipid phase comprising soybean oil, medium-chain triglycerides (MCT), olive oil and fish oil and less than 25 mg, preferably less than 20 mg, campesterol, less than 30 mg, preferably less than 25 mg, stigmasterol and less than 120 mg, preferably less than 100 mg, betasitosterol per 100 g of the lipid phase. The present disclosure also relates to the lipid emulsions according to the present disclosure for providing parenteral nutrition, in particular to neonates, as well as to methods for manufacturing the lipid emulsions according to the present disclosure.
-
2.发明公开公开(公告)号：US20240307298A1
公开(公告)日：2024-09-19
申请号：US18571198
申请日：2022-06-14
发明人： Edmundo BRITO DE LA FUENTE , Crispulo GALLEGOS-MONTES , Lida A. Quinchia-Bustamante , Getachew WELDEABEZGI , Mihaela TURCANU , Nadja Siegert
IPC分类号： A61K9/00 , A61K9/107 , A61K31/7004 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/44
CPC分类号： A61K9/0029 , A61K9/107 , A61K31/7004 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/22 , A61K47/24 , A61K47/44
摘要： The invention relates to a process for manufacturing oil-in-water emulsions with a PFATs value that remains below 0.05% for at least 24 hours, preferably for at least 48 hours after admixing the emulsions with an amino acid and a glucose solution suitable for parenteral administration.
-
3.发明申请MICROCAPSULES WITH POLYMERIC COATING COMPRISING A LIPID AND AN ACTIVE AGENT 审中-公开具有包含脂质和活性剂的聚合物涂层的微胶囊公开(公告)号：US20170000741A1
公开(公告)日：2017-01-05
申请号：US15106476
申请日：2014-12-19
IPC分类号： A61K9/50 , A61K31/19 , A23L33/115 , B65D51/28 , A23L29/10 , A23P10/35 , B65B7/28 , B65D47/06 , B01J13/14 , A23L29/231
CPC分类号： A61K9/50 , A23L29/10 , A23L29/231 , A23L33/115 , A23P10/35 , A61K9/16 , A61K9/5036 , A61K9/5089 , A61K31/19 , B01J13/14 , B65B7/28 , B65D47/06 , B65D51/28
摘要： The present invention relates to microcapsules and to methods for preparing them. The microcapsules comprise a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. In the matrix, a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid preferably having a melting point of at least 30° C. The microcapsules can be used as a medicament, dietary supplement or food additive, the microcapsules comprising a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. As above, a lipid and an active agent or a prodrug or salt thereof are embedded in the matrix, with the lipid preferably having a melting point of at least 30° C. Methods for treating diarrhea or preventing colon cancer comprising administering such microcapsules are also disclosed.
摘要翻译： 本发明涉及微胶囊及其制备方法。 微胶囊包含至少部分与包含多糖的聚合物基质部分交联的聚合物涂层。 在基质中，嵌入了脂质和活性剂或其前体药物或其盐，脂质优选具有至少30℃的熔点。微胶囊可用作药物，膳食补充剂或食品添加剂，微胶囊 包括与包含多糖的聚合物基质至少部分交联的聚合物涂层。 如上所述，脂质和活性剂或其前药或盐嵌入基质中，脂质优选具有至少30℃的熔点。治疗腹泻或预防结肠癌的方法包括施用这种微胶囊也是 披露
-
公开(公告)号：US20200306215A1
公开(公告)日：2020-10-01
申请号：US16341118
申请日：2017-10-05
发明人： Martin Westphal , Edmundo BRITO DE LA FUENTE , Crispulo Gallegos-Montes , Silke Baasner , Stefanie HONNDORF , Lida Quinchia
IPC分类号： A61K31/202 , A61K47/12 , A61K31/4745 , A61P35/00 , A61K31/513
摘要： The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.
-
公开(公告)号：US20200297638A1
公开(公告)日：2020-09-24
申请号：US16759310
申请日：2018-10-22
发明人： Getachew Assegehegn , Edmundo BRITO DE LA FUENTE , Crispulo GALLEGOS-MONTES , Lida A. Quinchia Bustamante
IPC分类号： A61K9/19 , A61K9/00 , A61K47/44 , A61K31/07 , A61K31/122 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/51 , A61K31/525 , A61K31/593 , A61K31/714 , A61K31/197 , A61K31/4188 , A61K31/455
摘要： The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.
-
公开(公告)号：US20200022941A1
公开(公告)日：2020-01-23
申请号：US16483730
申请日：2018-02-06
发明人： Martin Westphal , Silke Baasner , Stefanie HONNDORF , Edmundo BRITO DE LA FUENTE , Crispulo Gallegos-Montes , Lida Quinchia-Bustamante
摘要： The present invention relates to the treatment of liver diseases. In particular, it relates to a composition for use in treating and/or preventing a liver disease in a subject, wherein said composition comprises eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the ratio of EPA to DHA is at least 2:1.
-
公开(公告)号：US20190037903A1
公开(公告)日：2019-02-07
申请号：US16075294
申请日：2017-02-03
发明人： Edmundo BRITO DE LA FUENTE , Susanne KEIM , Ericka Pestana , Jose Maria Mainou-Sierra , Maria Femanda MARTINEZ-BOCK , Eileen WALLENFELS , Susanne Wiegand
摘要： A nutritional composition comprises a protein component, a lipid component and a carbohydrate component, minerals, vitamins and water, wherein the protein component comprises at least two different protein sources; wherein the first protein source is hydrolysed collagen; the lipid component provides at least 30 EN % of the total energy of the composition and the first source of protein represents 35-95 wt % based on the total weight of the protein component. The nutritional composition provides a homogeneous emulsion of high energy density (e.g. at least 3 kcal/mL) and high protein density (e.g. at least 14 g/100 mL).
-
公开(公告)号：US20180343912A1
公开(公告)日：2018-12-06
申请号：US15779376
申请日：2016-11-29
CPC分类号： A23L33/40 , A23L33/10 , A23L33/17 , A23V2002/00 , A61J15/00 , A61K38/00 , A61M2202/0482 , A23V2200/30 , A23V2200/32 , A23V2200/3322
摘要： Enteral tube feed for patients in an intensive care unit comprising a lipid component, a carbohydrate component and at least 30 EN % of a protein component based on the total energy content of the enteral tube feed, wherein the protein component comprises a peptide fraction consisting of di-, tri- and oligopeptides with a molecular weight of at most 1 kD, wherein the peptide fraction provides at least 10 EN % of the total energy content of the enteral composition and wherein the carbohydrate component predominantly consists of carbohydrates having a GI of ≤35 such as isomaltulose for use in treatment of ICU patients.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.015 秒)
